MicroRNAs Targeting Oncogenes Are Down-Regulated in Pancreatic Malignant Transformation from Benign Tumors

Background MicroRNA (miRNA) expression profiles have been described in pancreatic ductal adenocarcinoma (PDAC), but these have not been compared with pre-malignant pancreatic tumors. We wished to compare the miRNA expression signatures in pancreatic benign cystic tumors (BCT) of low and high malignant potential with PDAC, in order to identify miRNAs deregulated during PDAC development. The mechanistic consequences of miRNA dysregulation were further evaluated. Methods Tissue samples were obtained at a tertiary pancreatic unit from individuals with BCT and PDAC. MiRNA profiling was performed using a custom microarray and results were validated using RT-qPCR prior to evaluation of miRNA targets. Results Widespread miRNA down-regulation was observed in PDAC compared to low malignant potential BCT. We show that amongst those miRNAs down-regulated, miR-16, miR-126 and let-7d regulate known PDAC oncogenes (targeting BCL2, CRK and KRAS respectively). Notably, miR-126 also directly targets the KRAS transcript at a “seedless” binding site within its 3′UTR. In clinical specimens, miR-126 was strongly down-regulated in PDAC tissues, with an associated elevation in KRAS and CRK proteins. Furthermore, miR-21, a known oncogenic miRNA in pancreatic and other cancers, was not elevated in PDAC compared to serous microcystic adenoma (SMCA), but in both groups it was up-regulated compared to normal pancreas, implicating early up-regulation during malignant change. Conclusions Expression profiling revealed 21 miRNAs down-regulated in PDAC compared to SMCA, the most benign lesion that rarely progresses to invasive carcinoma. It appears that miR-21 up-regulation is an early event in the transformation from normal pancreatic tissue. MiRNA expression has the potential to distinguish PDAC from normal pancreas and BCT. Mechanistically the down-regulation of miR-16, miR-126 and let-7d promotes PDAC transformation by post-transcriptional up-regulation of crucial PDAC oncogenes. We show that miR-126 is able to directly target KRAS; re-expression has the potential as a therapeutic strategy against PDAC and other KRAS-driven cancers.

[1]  Gordon K Smyth,et al.  Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2004, Statistical applications in genetics and molecular biology.

[2]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[3]  Zhaohui Lu,et al.  The miR-217 microRNA functions as a potential tumor suppressor in pancreatic ductal adenocarcinoma by targeting KRAS. , 2010, Carcinogenesis.

[4]  D. Cunningham,et al.  Adjuvant treatment for resectable pancreatic cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R. Ach,et al.  Direct and sensitive miRNA profiling from low-input total RNA. , 2006, RNA.

[6]  L. Buscail,et al.  let-7 MicroRNA transfer in pancreatic cancer-derived cells inhibits in vitro cell proliferation but fails to alter tumor progression. , 2009, Human gene therapy.

[7]  Stijn van Dongen,et al.  miRBase: tools for microRNA genomics , 2007, Nucleic Acids Res..

[8]  G. Calin,et al.  Complex Patterns of Altered MicroRNA Expression during the Adenoma-Adenocarcinoma Sequence for Microsatellite-Stable Colorectal Cancer , 2011, Clinical Cancer Research.

[9]  J. Dagorn,et al.  MicroRNAs in Pancreatic Ductal Adenocarcinoma: New Diagnostic and Therapeutic Clues , 2008, Pancreatology.

[10]  O. Basturk,et al.  Pancreatic cysts: pathologic classification, differential diagnosis, and clinical implications. , 2009, Archives of pathology & laboratory medicine.

[11]  Gerald C. Chu,et al.  Context-dependent transformation of adult pancreatic cells by oncogenic K-Ras. , 2009, Cancer cell.

[12]  C. Nies,et al.  K-ras oncogene mutations indicate malignancy in cystic tumors of the pancreas. , 1998, Annals of surgery.

[13]  elliot k fishman,et al.  Benign pancreatic tumors. , 2007, The Surgical clinics of North America.

[14]  D. Shibata,et al.  Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes , 1988, Cell.

[15]  K. Ohuchida,et al.  MicroRNA, hsa-miR-200c, is an independent prognostic factor in pancreatic cancer and its upregulation inhibits pancreatic cancer invasion but increases cell proliferation , 2010, Molecular Cancer.

[16]  John L. Cameron,et al.  Resected Serous Cystic Neoplasms of the Pancreas: A Review of 158 Patients with Recommendations for Treatment , 2007, Journal of Gastrointestinal Surgery.

[17]  A. Bellizzi,et al.  Pancreatic cytopathology: a practical approach and review. , 2009, Archives of pathology & laboratory medicine.

[18]  R. Hruban,et al.  Cystic precursors to invasive pancreatic cancer , 2011, Nature Reviews Gastroenterology &Hepatology.

[19]  I. Kim,et al.  Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras. , 2010, International journal of radiation oncology, biology, physics.

[20]  F. Slack,et al.  RAS Is Regulated by the let-7 MicroRNA Family , 2005, Cell.

[21]  M. Fukayama,et al.  Clonality and K-ras mutation analyses of epithelia in intraductal papillary mucinous tumor and mucinous cystic tumor of the pancreas , 2002, Virchows Archiv.

[22]  M. Korc,et al.  Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues. , 2008, Clinical chemistry.

[23]  W. Gerald,et al.  Endogenous human microRNAs that suppress breast cancer metastasis , 2008, Nature.

[24]  S. D. Selcuklu,et al.  miR-21 as a key regulator of oncogenic processes. , 2009, Biochemical Society transactions.

[25]  S. T. Mees,et al.  MicroRNAs: Novel Diagnostic and Therapeutic Tools for Pancreatic Ductal Adenocarcinoma? , 2009, Annals of Surgical Oncology.

[26]  Mauro Biffoni,et al.  The miR-15a–miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities , 2008, Nature Medicine.

[27]  Eckart Meese,et al.  miRNAs in lung cancer - Studying complex fingerprints in patient's blood cells by microarray experiments , 2009, BMC Cancer.

[28]  Y. Hochberg.  A sharper Bonferroni procedure for multiple tests of significance , 1988 .

[29]  S. Leach,et al.  bcl-2 and p53 expression in resectable pancreatic adenocarcinomas: association with clinical outcome. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  D. Sahani,et al.  Cystic pancreatic lesions: classification and management. , 2009, Journal of the American College of Radiology.

[31]  Stijn van Dongen,et al.  miRBase: microRNA sequences, targets and gene nomenclature , 2005, Nucleic Acids Res..

[32]  Anna M. Krichevsky,et al.  miR-21: a small multi-faceted RNA , 2008, Journal of cellular and molecular medicine.

[33]  C. Morrison,et al.  MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B , 2007, Proceedings of the National Academy of Sciences.

[34]  C. Croce,et al.  MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. , 2007, JAMA.

[35]  C. Forsmark,et al.  Cystic neoplasms of the pancreas , 2000, Current treatment options in gastroenterology.

[36]  W. Fujibuchi,et al.  MiR-126 Acts as a Tumor Suppressor in Pancreatic Cancer Cells via the Regulation of ADAM9 , 2011, Molecular Cancer Research.

[37]  K. Satoh,et al.  [Point mutation of c-k-ras oncogene at codon 12 in mucin-producing cystic tumor of the pancreas]. , 1991, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology.

[38]  G. Nuovo,et al.  MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines. , 2008, Biochemical and biophysical research communications.

[39]  M. Hashizume,et al.  MicroRNA Expression as a Predictive Marker for Gemcitabine Response after Surgical Resection of Pancreatic Cancer , 2011, Annals of Surgical Oncology.

[40]  R. Hruban,et al.  An algorithmic approach to the diagnosis of pancreatic neoplasms. , 2009, Archives of pathology & laboratory medicine.

[41]  C. Langmead,et al.  ANGIOPOIETIN-2, A REGULATOR OF VASCULAR PERMEABILITY IN INFLAMMATION IS ELEVATED IN SEVERE ACUTE PANCREATITIS AND IS ASSOCIATED WITH SYSTEMIC ORGAN FAILURE , 2008 .

[42]  Y. Atomi,et al.  An increased high-mobility group A2 expression level is associated with malignant phenotype in pancreatic exocrine tissue , 2003, British Journal of Cancer.

[43]  C. Croce,et al.  miR-15a and miR-16-1 in cancer: discovery, function and future perspectives , 2010, Cell Death and Differentiation.

[44]  Y. Akao,et al.  let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. , 2006, Biological & pharmaceutical bulletin.

[45]  Oliver Hofmann,et al.  miR-24 Inhibits cell proliferation by targeting E2F2, MYC, and other cell-cycle genes via binding to "seedless" 3'UTR microRNA recognition elements. , 2009, Molecular cell.

[46]  E. Hudson,et al.  Pancreatic cancer within a UK cancer network with special emphasis on locally advanced non-metastatic pancreatic cancer. , 2008, Clinical oncology (Royal College of Radiologists (Great Britain)).

[47]  S. Chari,et al.  International Consensus Guidelines for Management of Intraductal Papillary Mucinous Neoplasms and Mucinous Cystic Neoplasms of the Pancreas , 2006, Pancreatology.

[48]  Sonja Vorwerk,et al.  Microfluidic-based enzymatic on-chip labeling of miRNAs. , 2008, New biotechnology.

[49]  C. Croce,et al.  Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[50]  M. Nakao,et al.  HMGA2 maintains oncogenic RAS-induced epithelial-mesenchymal transition in human pancreatic cancer cells. , 2009, The American journal of pathology.

[51]  G. Hannon,et al.  The estrogen receptor-α-induced microRNA signature regulates itself and its transcriptional response , 2009, Proceedings of the National Academy of Sciences.

[52]  L. Lim,et al.  MicroRNA targeting specificity in mammals: determinants beyond seed pairing. , 2007, Molecular cell.

[53]  A. Abioye,et al.  Pancreatic carcinoma. , 2020, Journal of the National Medical Association.

[54]  M. Goggins.  Identifying molecular markers for the early detection of pancreatic neoplasia. , 2007, Seminars in oncology.

[55]  Yvonne Tay,et al.  A Pattern-Based Method for the Identification of MicroRNA Binding Sites and Their Corresponding Heteroduplexes , 2006, Cell.

[56]  David Tuck,et al.  A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis. , 2011, The Lancet. Oncology.

[57]  Gordon K. Smyth,et al.  Use of within-array replicate spots for assessing differential expression in microarray experiments , 2005, Bioinform..

[58]  Jia Yu,et al.  miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer. , 2010, Cancer research.

[59]  George A Calin,et al.  MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer. , 2009, Cancer research.

[60]  G. Goldberg,et al.  Regulation of miRNA expression by Src and contact normalization: effects on nonanchored cell growth and migration , 2009, Oncogene.

[61]  M. Mino‐Kenudson,et al.  Mucin-producing neoplasms of the pancreas: an analysis of distinguishing clinical and epidemiologic characteristics. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[62]  C. Croce,et al.  miR-15 and miR-16 induce apoptosis by targeting BCL2. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[63]  H. Horvitz,et al.  MicroRNA expression profiles classify human cancers , 2005, Nature.

[64]  Mirko H. H. Schmidt,et al.  miR-126 and miR-126*: New Players in Cancer , 2010, TheScientificWorldJournal.

[65]  Liu Hong,et al.  miR‐15b and miR‐16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells , 2008, International journal of cancer.

[66]  David P. Bartel,et al.  Supporting Online Material Materials and Methods Fig. S1 Tables S1 and S2 References Database S1 Disrupting the Pairing between Let-7 and Hmga2 Enhances Oncogenic Transformation , 2022 .

[67]  X. Chen,et al.  Role of miR-143 targeting KRAS in colorectal tumorigenesis , 2009, Oncogene.

[68]  N. Adsay,et al.  Cystic lesions of the pancreas , 2007, Modern Pathology.

[69]  T. Davison,et al.  MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma , 2007, Oncogene.

[70]  Shu Liu,et al.  Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway. , 2010, Genes & development.

[71]  G. Tonini,et al.  Transcribed-ultra conserved region expression profiling from low-input total RNA , 2010, BMC Genomics.

[72]  L. Buscail,et al.  MicroRNA-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions. , 2010, Clinical chemistry.

[73]  Patricia Greninger,et al.  A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. , 2009, Cancer cell.

[74]  Terence P. Speed,et al.  A comparison of normalization methods for high density oligonucleotide array data based on variance and bias , 2003, Bioinform..

[75]  Jianfang Li,et al.  miR-126 functions as a tumour suppressor in human gastric cancer. , 2010, Cancer letters.

[76]  S. Nomoto,et al.  Immunohistochemical and molecular biological studies of serous cystadenoma of the pancreas. , 1998, Pancreas.

[77]  R. Hruban,et al.  Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. , 2007, Cancer cell.

[78]  Wendy Frankel,et al.  MicroRNA-21 is Overexpressed in Pancreatic Cancer and a Potential Predictor of Survival , 2008, Journal of Gastrointestinal Surgery.

[79]  Yusuke Yamamoto,et al.  Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.